Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1958 2
1961 2
1962 2
1964 2
1965 2
1966 6
1967 5
1968 6
1969 3
1970 10
1971 2
1972 10
1973 2
1974 4
1975 9
1976 11
1977 15
1978 17
1979 15
1980 17
1981 17
1982 22
1983 29
1984 33
1985 53
1986 49
1987 67
1988 60
1989 65
1990 59
1991 63
1992 60
1993 65
1994 55
1995 73
1996 76
1997 72
1998 87
1999 104
2000 94
2001 93
2002 102
2003 131
2004 115
2005 155
2006 158
2007 165
2008 179
2009 183
2010 219
2011 263
2012 270
2013 329
2014 321
2015 301
2016 286
2017 278
2018 241
2019 263
2020 305
2021 356
2022 364
2023 317
2024 316
2025 319
2026 147

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

6,761 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean hamamoto n[au] (51 results)?
Zongertinib in Previously Treated HER2-Mutant Non-Small-Cell Lung Cancer.
Heymach JV, Ruiter G, Ahn MJ, Girard N, Smit EF, Planchard D, Wu YL, Cho BC, Yamamoto N, Sabari JK, Zhao Y, Tu HY, Yoh K, Nadal E, Sadrolhefazi B, Rohrbacher M, von Wangenheim U, Eigenbrod-Giese S, Zugazagoitia J; Beamion LUNG-1 Investigators. Heymach JV, et al. Among authors: yamamoto n. N Engl J Med. 2025 Jun 19;392(23):2321-2333. doi: 10.1056/NEJMoa2503704. Epub 2025 Apr 28. N Engl J Med. 2025. PMID: 40293180 Clinical Trial.
The Japanese Critical Care Nutrition Guideline 2024.
Nakamura K, Yamamoto R, Higashibeppu N, Yoshida M, Tatsumi H, Shimizu Y, Izumino H, Oshima T, Hatakeyama J, Ouchi A, Tsutsumi R, Tsuboi N, Yamamoto N, Nozaki A, Asami S, Takatani Y, Yamada K, Matsuishi Y, Takauji S, Tampo A, Terasaka Y, Sato T, Okamoto S, Sakuramoto H, Miyagi T, Aki K, Ota H, Watanabe T, Nakanishi N, Ohbe H, Narita C, Takeshita J, Sagawa M, Tsunemitsu T, Matsushima S, Kobashi D, Yanagita Y, Watanabe S, Murata H, Taguchi A, Hiramoto T, Ichimaru S, Takeuchi M, Kotani J. Nakamura K, et al. Among authors: yamamoto n. J Intensive Care. 2025 Mar 21;13(1):18. doi: 10.1186/s40560-025-00785-z. J Intensive Care. 2025. PMID: 40119480 Free PMC article. Review.
First-in-human study of AMG 193, an MTA-cooperative PRMT5 inhibitor, in patients with MTAP-deleted solid tumors: results from phase I dose exploration.
Rodon J, Prenen H, Sacher A, Villalona-Calero M, Penel N, El Helali A, Rottey S, Yamamoto N, Ghiringhelli F, Goebeler ME, Doi T, Postel-Vinay S, Lin CC, Liu C, Chuang CH, Keyvanjah K, Eggert T, O'Neil BH. Rodon J, et al. Among authors: yamamoto n. Ann Oncol. 2024 Dec;35(12):1138-1147. doi: 10.1016/j.annonc.2024.08.2339. Epub 2024 Sep 16. Ann Oncol. 2024. PMID: 39293516 Free article. Clinical Trial.
HER2-Selective Tyrosine Kinase Inhibitor, Zongertinib (BI 1810631), in Patients With Advanced/Metastatic Solid Tumors With HER2 Alterations: A Phase Ia Dose-Escalation Study.
Heymach JV, Opdam F, Barve M, Tu HY, Wu YL, Berz D, Schröter L, Botilde Y, Sadrolhefazi B, Serra J, Yoh K, Yamamoto N. Heymach JV, et al. Among authors: yamamoto n. J Clin Oncol. 2025 Apr 10;43(11):1337-1347. doi: 10.1200/JCO-24-01727. Epub 2025 Mar 3. J Clin Oncol. 2025. PMID: 40030100 Free PMC article. Clinical Trial.
An investigation of extended-interval dosing of atezolizumab in Japanese patients with advanced solid tumors: safety and pharmacokinetics of a dose of 1680 mg every 4 weeks.
Kondo S, Kitano S, Sato J, Katsuya Y, Kogawa T, Mizugaki H, Miyamoto I, Iwasawa S, Imaizumi T, Tomita H, Murakami C, Miyake T, Yamamoto N. Kondo S, et al. Among authors: yamamoto n. Invest New Drugs. 2025 Jun;43(3):602-608. doi: 10.1007/s10637-024-01498-0. Epub 2025 May 1. Invest New Drugs. 2025. PMID: 40310568 Free PMC article.
Identifying consensus and areas for future research in chondrosarcoma : a report from the Birmingham Orthopaedic Oncology Meeting.
Jeys LM, Morris GV, Kurisunkal VJ, Botello E, Boyle RA, Ebeid W, Houdek MT, Puri A, Ruggieri P, Brennan B; BOOM Consensus Meeting Participants; Laitinen MK, Abad Repiso S, Abdelbary H, Abiad Mejia A, Abood AA, Abril Martin JC, Abudu A, Abu Elhamd A, Acosta M, Ae K, Agarwal M, Ajit Singh V, Akiyama T, Alshaygy I, Albergo JI, Alexander J, Alfaro PA, Alpan B, Amaya-Valero J, Anderson M, Andreou D, Annabell L, Anthony C, Aoude A, Arteagoitia-Colino I, Asavamongkolkul A, Aston W, Asua Mentxaka L, Azzopardi C, Baad-Hansen T, Badr IT, Baixauli-Garcia F, Baker G, Balach T, Baldi GG, Barry J, Basile G, Bastoni S, Basuki M, Bauer H, Bayliss L, Becker RG, Bedi A, Benevenia J, Bengoa F, Bergh P, Bergovec M, Bernthal N, Binitie O, Boddie D, Boffano M, Bonilla Huertas P, Borgognoni AB, Botchu R, Bramer J, Brar R, Branford-White H, Broekhuis D, Broida SE, Budny T, Burke ZD, Cabrolier J, Calvo-Haro JA, Calvo Tapies JR, Cardoso R, Carey Smith R, Carvallo PI, Casales Fresenga N, Casanova JM, Ceballos O, Cebrian Parra JL, Chacon Cartaya S, Chan CM, Cho YJ, Choong P, Chung YG, Ciechanowicz D, Clara-Altamirano MA, Clever D, Colina SM, Consuegra L, Couch C, Cribb G, Cuervo C, Cusick LA, Dadia S, Dagher… See abstract for full author list ➔ Jeys LM, et al. Among authors: yamamoto n. Bone Joint J. 2025 Feb 1;107-B(2):246-252. doi: 10.1302/0301-620X.107B2.BJJ-2024-0643.R1. Bone Joint J. 2025. PMID: 39889743
In reply.
Hayashi M, Yamamoto N, Shiroshita A. Hayashi M, et al. Among authors: yamamoto n. Ann Emerg Med. 2025 Jan;85(1):96-97. doi: 10.1016/j.annemergmed.2024.08.001. Ann Emerg Med. 2025. PMID: 39706612 No abstract available.
Serum VEGF-A as a biomarker for the addition of bevacizumab to chemo-immunotherapy in metastatic NSCLC.
Tanaka K, Sugisaka J, Shiraishi Y, Watanabe Y, Daga H, Azuma K, Nishino K, Mori M, Ota T, Saito H, Hata A, Sakaguchi T, Kozuki T, Akamatsu H, Matsumoto H, Tachihara M, Wakuda K, Sato Y, Ozaki T, Tsuchiya-Kawano Y, Yamamoto N, Nakagawa K, Okamoto I. Tanaka K, et al. Among authors: yamamoto n. Nat Commun. 2025 Mar 22;16(1):2825. doi: 10.1038/s41467-025-58186-7. Nat Commun. 2025. PMID: 40121197 Free PMC article. Clinical Trial.
Adjuvant Durvalumab in Completely Resected Early-Stage Non-Small Cell Lung Cancer.
Goss GD, Darling GE, Westeel V, Nakagawa K, Massutí B, Perrone F, McLachlan SA, Kang JH, Wu YL, Dingemans AC, Dziadziuszko R, Greillier L, Okada M, Audigier-Valette C, Sugawara S, Nadal E, Catino A, Toffart AC, Mitsudomi T, Whittom R, Domine M, Yamamoto N, Molinier O, Morin F, Bradbury PA, Stockler MR, Ding K, O'Callaghan CJ. Goss GD, et al. Among authors: yamamoto n. J Clin Oncol. 2026 Mar;44(7):553-564. doi: 10.1200/JCO-25-01828. Epub 2026 Jan 13. J Clin Oncol. 2026. PMID: 41529222
HMGA2 and protein leucine methylation drive pancreatic cancer lineage plasticity.
Dobersch S, Yamamoto N, Schutter A, Cavender SM, Robertson TM, Kartha N, Samraj AN, Doron B, Poole LA, Wladyka CL, Zhang A, Jang GH, Mahalingam AH, Barreto G, Raghavan S, Narla G, Notta F, Eisenman RN, Hsieh AC, Kugel S. Dobersch S, et al. Among authors: yamamoto n. Nat Commun. 2025 May 26;16(1):4866. doi: 10.1038/s41467-025-60129-1. Nat Commun. 2025. PMID: 40419509 Free PMC article.
6,761 results